Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.44 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396731 | 0.98 | MAPK1 (0.58) | MAPK1PARP1PARP2PARP3KDM4E | |
| Hydrochloric Acid SCHEMBL23071632 | 0.85 | TYK2 (0.49) | MAPK1KDM4EALDH1A1SMN1; SMN2RIPK2 | |
| SCHEMBL1137068 | 0.84 | KDM4E (0.54) | MAPK1KDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30174215 | 0.83 | KDM4E (0.45) | MAPK1PARP1PARP2PARP3KDM4E | |
| SCHEMBL1161158 | 0.83 | TYK2 (0.50) | MAPK1KDM4EALDH1A1SMN1; SMN2RIPK2 | |
| SCHEMBL15327933 | 0.83 | MAPK1 (0.54) | MAPK1PARP1PARP2PARP3KDM4E | |
| SCHEMBL15328054 | 0.83 | MAPK1 (0.43) | MAPK1PARP1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL10707587 | 0.81 | MKNK1 (0.48) | MAPK1TDP1SIRT1 | |
| SCHEMBL15328279 | 0.81 | MAPK1 (0.55) | MAPK1PARP1PARP2PARP3KDM4E | |
| SCHEMBL15327967 | 0.81 | KDM4E (0.63) | MAPK1PARP1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116685324-A | Pharmaceutical composition for preventing or treating pancreatic cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116390729-A | Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115916210-A | Pharmaceutical composition for preventing or treating small cell lung cancer associated with RON mutation and method of using the same | 伟迈可生物有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4154892-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SMALL-CELL LUNG CANCER ASSOCIATED WITH RON MUTANTS AND METHOD USING SAME | Wellmarker Bio Co., Ltd. (KR) | 2023-03-29 | — | — | EP | disclosed |
| EP-4154891-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTATION, AND METHOD USING SAME | Wellmarker Bio Co., Ltd. (KR) | 2023-03-29 | — | — | EP | disclosed |
| EP-4154890-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME | Wellmarker Bio Co., Ltd. (KR) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022235063-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RON-MUTATION-ASSOCIATED BILIARY TRACT CANCER | 웰마커바이오 주식회사 | 2022-11-10 | — | — | WO | disclosed |
| CN-115209900-A | Pharmaceutical composition for preventing or treating cancer in which KRAS mutation and activated RON are present | 伟迈可生物有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO, LTD. (KR) | 2022-09-15 | — | — | US | disclosed |
| CN-115003307-A | Pharmaceutical composition for preventing or treating cancers associated with KRAS mutations | 伟迈可生物有限公司 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PRKACA, MAP4K5, MAPKAPK5 | PARP1 3210/4885ADRA1D 689/4885MAPK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.